Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19.
Mayo Clin Proc Innov Qual Outcomes
; 6(5): 484-487, 2022 Oct.
Article
in English
| MEDLINE | ID: covidwho-2049628
ABSTRACT
Although corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), the studies demonstrating the mortality-benefit ratio of corticosteroids were limited to fully evaluate their adverse effects. To determine the severity of corticosteroid-induced hyperglycemia in patients with and without diabetes mellitus, we retrospectively collected data from the medical records of patients hospitalized with COVID-19 before and after corticosteroids were the standard of care. Corticosteroid-induced hyperglycemia was more severe in patients hospitalized with COVID-19 with diabetes than those without diabetes. Additionally, patients with diabetes required higher doses of correctional insulin per day when on corticosteroid therapy, suggesting that intensive point-of-care glucose monitoring could be limited in patients without diabetes mellitus and support cautionary use of corticosteroids in patients with COVID-19 discharged with supplemental oxygen.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Mayo Clin Proc Innov Qual Outcomes
Year:
2022
Document Type:
Article
Affiliation country:
J.mayocpiqo.2022.07.004
Similar
MEDLINE
...
LILACS
LIS